You are here

Article Text

Article menu
Download PDFPDF
Letter
Anti-annexin V antibodies in patients with cerebrovascular disease
  1. N Gašperšič1,
  2. U Rot2,
  3. S Čučnik1,
  4. T Kveder1,
  5. B Božič1,
  6. B Rozman1
  1. 1Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia
  2. 2Department of Neurology, University Medical Centre, Ljubljana, Slovenia
  1. Correspondence to:
    Professor B Rozman, University Medical Centre, Department of Rheumatology, Vodnikova 62, SI-1000 Ljubljana, Slovenia;
    kc.lj.rozman{at}siol.net

https://doi.org/10.1136/ard.62.2.188

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Annexin V (ANXV) is a protein with a high affinity for negatively charged phospholipids and shows in vitro a potent anticoagulant activity. It has been suggested that it has a significant role in the prevention of arteriovenous thromboses or fetal loss, or both.1 Increased levels of antibodies against ANXV (aANXV) have been reported in patients with different systemic autoimmune disorders2–4 as well as in women with recurrent fetal loss and pre-eclampsia.5 The presence of aANXV in patients with thromboembolic cerebrovascular disease (CVD), however, has not yet been described. We report on two patients with CVD who had evidently raised levels of IgG aANXV, whereas all the other tested antiphospholipid antibodies (aPL) were negative.

    We examined 37 young patients with no evident systemic autoimmune …

    View Full Text